Among them, increasing evidence has shown that RNF2 contributes to influence clinical characteristics of many types of cancers, including hepatocellular carcinoma, melanoma, prostate cancer, breast cancer, pancreatic cancer, gastric cancer and bladder urothelial carcinoma (29, 35, 36). Here, RNF2 is linked to prostate carcinoma.